A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome
Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations...
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2021-08, Vol.26 (8), p.3778-3794 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3794 |
---|---|
container_issue | 8 |
container_start_page | 3778 |
container_title | Molecular psychiatry |
container_volume | 26 |
creator | Cursano, Silvia Battaglia, Chiara R. Urrutia-Ruiz, Carolina Grabrucker, Stefanie Schön, Michael Bockmann, Jürgen Braumüller, Sonja Radermacher, Peter Roselli, Francesco Huber-Lang, Markus Boeckers, Tobias M. |
description | Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations in the central nervous system. Up to 5 days after trauma, we observed a transient 50% decrease in the number of excitatory synapses specifically in hippocampal pyramidal neurons accompanied by alterations in attention and motor activity and disruption of contextual memory consolidation. In parallel, hippocampal corticotropin-releasing hormone (CRH) expression was highly upregulated, and brain-derived neurotrophic factor (BDNF) levels were significantly reduced. In vitro experiments revealed that CRH application induced neuronal autophagy with rapid lysosomal degradation of BDNF via the NF-κB pathway. The subsequent synaptic loss was rescued by BDNF as well as by specific NF-κB and CRH receptor 1 (CRHR1) antagonists. In vivo, the chronic application of a CRHR1 antagonist after TxT resulted in reversal of the observed histological, molecular, and behavioral alterations. The data suggest that neuropsychiatric syndromes (i.e., delirium) after peripheral trauma might be at least in part due to the activation of the hippocampal CRH/NF-κB/BDNF pathway, which results in a dramatic loss of synaptic contacts. The successful rescue by stress hormone receptor antagonists should encourage clinical trials focusing on trauma-induced delirium and/or other posttraumatic syndromes. |
doi_str_mv | 10.1038/s41380-020-0659-y |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A680437182</galeid><sourcerecordid>A680437182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c603t-1d42edefb3321534d985b2fb4bd657103829490c6ddcd94f1da34711e10f843f3</originalsourceid><addsrcrecordid>eNp1kl1rFTEQhoMotlZ_gDey4I03W_O92RvhcFArFAqlvQ7ZJHuaupsck93C_ntnObW1YgkhYeaZN7yTQeg9wacEM_W5cMIUrjGFLUVbLy_QMeGNrIVo1Eu4MwhyovgRelPKLcZrUrxGR4xiQYTAx-hmU20vzy5JZeJkdimGMlX77O98nEpVlmj2U7DVkEoBwlWjH1NeKuf7YAMQIVammrKZR1OH6GbrHSSHkMM81kP46VcNl9Po36JXvRmKf3d_nqDrb1-vtmf1-cX3H9vNeW0lZlNNHKce5DvGKBGMu1aJjvYd75wUzeqatrzFVjpnXct74gzjDSGe4F5x1rMT9OWgu5-70TsLRrIZ9D6H0eRFJxP000wMN3qX7rSCfrSSgcCne4Gcfs2-THoMxfphMNGnuWjKBG9YK2UD6Md_0Ns05wj2NBUKCCkwf6R2ZvA6xD7Bu3YV1RupAGiIokCd_oeC5fwYbIrQcYg_KSCHApvhd7LvHzwSrNdG6cN4aBgPvY6HXqDmw9_Neaj4Mw8A0ANQIBV3Pj86el71N-I7xYE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2586676504</pqid></control><display><type>article</type><title>A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Cursano, Silvia ; Battaglia, Chiara R. ; Urrutia-Ruiz, Carolina ; Grabrucker, Stefanie ; Schön, Michael ; Bockmann, Jürgen ; Braumüller, Sonja ; Radermacher, Peter ; Roselli, Francesco ; Huber-Lang, Markus ; Boeckers, Tobias M.</creator><creatorcontrib>Cursano, Silvia ; Battaglia, Chiara R. ; Urrutia-Ruiz, Carolina ; Grabrucker, Stefanie ; Schön, Michael ; Bockmann, Jürgen ; Braumüller, Sonja ; Radermacher, Peter ; Roselli, Francesco ; Huber-Lang, Markus ; Boeckers, Tobias M.</creatorcontrib><description>Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations in the central nervous system. Up to 5 days after trauma, we observed a transient 50% decrease in the number of excitatory synapses specifically in hippocampal pyramidal neurons accompanied by alterations in attention and motor activity and disruption of contextual memory consolidation. In parallel, hippocampal corticotropin-releasing hormone (CRH) expression was highly upregulated, and brain-derived neurotrophic factor (BDNF) levels were significantly reduced. In vitro experiments revealed that CRH application induced neuronal autophagy with rapid lysosomal degradation of BDNF via the NF-κB pathway. The subsequent synaptic loss was rescued by BDNF as well as by specific NF-κB and CRH receptor 1 (CRHR1) antagonists. In vivo, the chronic application of a CRHR1 antagonist after TxT resulted in reversal of the observed histological, molecular, and behavioral alterations. The data suggest that neuropsychiatric syndromes (i.e., delirium) after peripheral trauma might be at least in part due to the activation of the hippocampal CRH/NF-κB/BDNF pathway, which results in a dramatic loss of synaptic contacts. The successful rescue by stress hormone receptor antagonists should encourage clinical trials focusing on trauma-induced delirium and/or other posttraumatic syndromes.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/s41380-020-0659-y</identifier><identifier>PMID: 32051550</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/105 ; 13/51 ; 14/28 ; 631/378 ; 631/477 ; 64/60 ; 692/699/476/1414 ; 82/79 ; Age ; Animals ; Antipsychotic drugs ; Autophagy ; Behavioral Sciences ; Biological Psychology ; Brain-derived neurotrophic factor ; Central nervous system ; Clinical trials ; Cognition ; Complications and side effects ; Corticotropin releasing hormone ; Delirium ; Development and progression ; Dosage and administration ; Drug therapy ; Health aspects ; Hippocampus ; Hippocampus (Brain) ; Hormone receptors ; Humans ; Lysosomes ; Medicine ; Medicine & Public Health ; Memory ; Memory Disorders - drug therapy ; Memory Disorders - etiology ; Memory, Disorders of ; Mice ; Motor activity ; Neurons ; Neurosciences ; NF-κB protein ; Phagocytosis ; Pharmacotherapy ; Physiological aspects ; Prevention ; Psychiatry ; Pyramidal cells ; Receptors, Corticotropin-Releasing Hormone ; Risk factors ; Synapses ; Syndrome ; Thorax ; Trauma ; Wounds and injuries</subject><ispartof>Molecular psychiatry, 2021-08, Vol.26 (8), p.3778-3794</ispartof><rights>The Author(s) 2020</rights><rights>2020. The Author(s).</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c603t-1d42edefb3321534d985b2fb4bd657103829490c6ddcd94f1da34711e10f843f3</citedby><cites>FETCH-LOGICAL-c603t-1d42edefb3321534d985b2fb4bd657103829490c6ddcd94f1da34711e10f843f3</cites><orcidid>0000-0002-1486-8535 ; 0000-0001-9935-6899</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32051550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cursano, Silvia</creatorcontrib><creatorcontrib>Battaglia, Chiara R.</creatorcontrib><creatorcontrib>Urrutia-Ruiz, Carolina</creatorcontrib><creatorcontrib>Grabrucker, Stefanie</creatorcontrib><creatorcontrib>Schön, Michael</creatorcontrib><creatorcontrib>Bockmann, Jürgen</creatorcontrib><creatorcontrib>Braumüller, Sonja</creatorcontrib><creatorcontrib>Radermacher, Peter</creatorcontrib><creatorcontrib>Roselli, Francesco</creatorcontrib><creatorcontrib>Huber-Lang, Markus</creatorcontrib><creatorcontrib>Boeckers, Tobias M.</creatorcontrib><title>A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations in the central nervous system. Up to 5 days after trauma, we observed a transient 50% decrease in the number of excitatory synapses specifically in hippocampal pyramidal neurons accompanied by alterations in attention and motor activity and disruption of contextual memory consolidation. In parallel, hippocampal corticotropin-releasing hormone (CRH) expression was highly upregulated, and brain-derived neurotrophic factor (BDNF) levels were significantly reduced. In vitro experiments revealed that CRH application induced neuronal autophagy with rapid lysosomal degradation of BDNF via the NF-κB pathway. The subsequent synaptic loss was rescued by BDNF as well as by specific NF-κB and CRH receptor 1 (CRHR1) antagonists. In vivo, the chronic application of a CRHR1 antagonist after TxT resulted in reversal of the observed histological, molecular, and behavioral alterations. The data suggest that neuropsychiatric syndromes (i.e., delirium) after peripheral trauma might be at least in part due to the activation of the hippocampal CRH/NF-κB/BDNF pathway, which results in a dramatic loss of synaptic contacts. The successful rescue by stress hormone receptor antagonists should encourage clinical trials focusing on trauma-induced delirium and/or other posttraumatic syndromes.</description><subject>13/105</subject><subject>13/51</subject><subject>14/28</subject><subject>631/378</subject><subject>631/477</subject><subject>64/60</subject><subject>692/699/476/1414</subject><subject>82/79</subject><subject>Age</subject><subject>Animals</subject><subject>Antipsychotic drugs</subject><subject>Autophagy</subject><subject>Behavioral Sciences</subject><subject>Biological Psychology</subject><subject>Brain-derived neurotrophic factor</subject><subject>Central nervous system</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Complications and side effects</subject><subject>Corticotropin releasing hormone</subject><subject>Delirium</subject><subject>Development and progression</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>Hippocampus</subject><subject>Hippocampus (Brain)</subject><subject>Hormone receptors</subject><subject>Humans</subject><subject>Lysosomes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Memory</subject><subject>Memory Disorders - drug therapy</subject><subject>Memory Disorders - etiology</subject><subject>Memory, Disorders of</subject><subject>Mice</subject><subject>Motor activity</subject><subject>Neurons</subject><subject>Neurosciences</subject><subject>NF-κB protein</subject><subject>Phagocytosis</subject><subject>Pharmacotherapy</subject><subject>Physiological aspects</subject><subject>Prevention</subject><subject>Psychiatry</subject><subject>Pyramidal cells</subject><subject>Receptors, Corticotropin-Releasing Hormone</subject><subject>Risk factors</subject><subject>Synapses</subject><subject>Syndrome</subject><subject>Thorax</subject><subject>Trauma</subject><subject>Wounds and injuries</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kl1rFTEQhoMotlZ_gDey4I03W_O92RvhcFArFAqlvQ7ZJHuaupsck93C_ntnObW1YgkhYeaZN7yTQeg9wacEM_W5cMIUrjGFLUVbLy_QMeGNrIVo1Eu4MwhyovgRelPKLcZrUrxGR4xiQYTAx-hmU20vzy5JZeJkdimGMlX77O98nEpVlmj2U7DVkEoBwlWjH1NeKuf7YAMQIVammrKZR1OH6GbrHSSHkMM81kP46VcNl9Po36JXvRmKf3d_nqDrb1-vtmf1-cX3H9vNeW0lZlNNHKce5DvGKBGMu1aJjvYd75wUzeqatrzFVjpnXct74gzjDSGe4F5x1rMT9OWgu5-70TsLRrIZ9D6H0eRFJxP000wMN3qX7rSCfrSSgcCne4Gcfs2-THoMxfphMNGnuWjKBG9YK2UD6Md_0Ns05wj2NBUKCCkwf6R2ZvA6xD7Bu3YV1RupAGiIokCd_oeC5fwYbIrQcYg_KSCHApvhd7LvHzwSrNdG6cN4aBgPvY6HXqDmw9_Neaj4Mw8A0ANQIBV3Pj86el71N-I7xYE</recordid><startdate>20210801</startdate><enddate>20210801</enddate><creator>Cursano, Silvia</creator><creator>Battaglia, Chiara R.</creator><creator>Urrutia-Ruiz, Carolina</creator><creator>Grabrucker, Stefanie</creator><creator>Schön, Michael</creator><creator>Bockmann, Jürgen</creator><creator>Braumüller, Sonja</creator><creator>Radermacher, Peter</creator><creator>Roselli, Francesco</creator><creator>Huber-Lang, Markus</creator><creator>Boeckers, Tobias M.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1486-8535</orcidid><orcidid>https://orcid.org/0000-0001-9935-6899</orcidid></search><sort><creationdate>20210801</creationdate><title>A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome</title><author>Cursano, Silvia ; Battaglia, Chiara R. ; Urrutia-Ruiz, Carolina ; Grabrucker, Stefanie ; Schön, Michael ; Bockmann, Jürgen ; Braumüller, Sonja ; Radermacher, Peter ; Roselli, Francesco ; Huber-Lang, Markus ; Boeckers, Tobias M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c603t-1d42edefb3321534d985b2fb4bd657103829490c6ddcd94f1da34711e10f843f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>13/105</topic><topic>13/51</topic><topic>14/28</topic><topic>631/378</topic><topic>631/477</topic><topic>64/60</topic><topic>692/699/476/1414</topic><topic>82/79</topic><topic>Age</topic><topic>Animals</topic><topic>Antipsychotic drugs</topic><topic>Autophagy</topic><topic>Behavioral Sciences</topic><topic>Biological Psychology</topic><topic>Brain-derived neurotrophic factor</topic><topic>Central nervous system</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Complications and side effects</topic><topic>Corticotropin releasing hormone</topic><topic>Delirium</topic><topic>Development and progression</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>Hippocampus</topic><topic>Hippocampus (Brain)</topic><topic>Hormone receptors</topic><topic>Humans</topic><topic>Lysosomes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Memory</topic><topic>Memory Disorders - drug therapy</topic><topic>Memory Disorders - etiology</topic><topic>Memory, Disorders of</topic><topic>Mice</topic><topic>Motor activity</topic><topic>Neurons</topic><topic>Neurosciences</topic><topic>NF-κB protein</topic><topic>Phagocytosis</topic><topic>Pharmacotherapy</topic><topic>Physiological aspects</topic><topic>Prevention</topic><topic>Psychiatry</topic><topic>Pyramidal cells</topic><topic>Receptors, Corticotropin-Releasing Hormone</topic><topic>Risk factors</topic><topic>Synapses</topic><topic>Syndrome</topic><topic>Thorax</topic><topic>Trauma</topic><topic>Wounds and injuries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cursano, Silvia</creatorcontrib><creatorcontrib>Battaglia, Chiara R.</creatorcontrib><creatorcontrib>Urrutia-Ruiz, Carolina</creatorcontrib><creatorcontrib>Grabrucker, Stefanie</creatorcontrib><creatorcontrib>Schön, Michael</creatorcontrib><creatorcontrib>Bockmann, Jürgen</creatorcontrib><creatorcontrib>Braumüller, Sonja</creatorcontrib><creatorcontrib>Radermacher, Peter</creatorcontrib><creatorcontrib>Roselli, Francesco</creatorcontrib><creatorcontrib>Huber-Lang, Markus</creatorcontrib><creatorcontrib>Boeckers, Tobias M.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cursano, Silvia</au><au>Battaglia, Chiara R.</au><au>Urrutia-Ruiz, Carolina</au><au>Grabrucker, Stefanie</au><au>Schön, Michael</au><au>Bockmann, Jürgen</au><au>Braumüller, Sonja</au><au>Radermacher, Peter</au><au>Roselli, Francesco</au><au>Huber-Lang, Markus</au><au>Boeckers, Tobias M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2021-08-01</date><risdate>2021</risdate><volume>26</volume><issue>8</issue><spage>3778</spage><epage>3794</epage><pages>3778-3794</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>Older patients with severe physical trauma are at high risk of developing neuropsychiatric syndromes with global impairment of cognition, attention, and consciousness. We employed a thoracic trauma (TxT) mouse model and thoroughly analyzed age-dependent spatial and temporal posttraumatic alterations in the central nervous system. Up to 5 days after trauma, we observed a transient 50% decrease in the number of excitatory synapses specifically in hippocampal pyramidal neurons accompanied by alterations in attention and motor activity and disruption of contextual memory consolidation. In parallel, hippocampal corticotropin-releasing hormone (CRH) expression was highly upregulated, and brain-derived neurotrophic factor (BDNF) levels were significantly reduced. In vitro experiments revealed that CRH application induced neuronal autophagy with rapid lysosomal degradation of BDNF via the NF-κB pathway. The subsequent synaptic loss was rescued by BDNF as well as by specific NF-κB and CRH receptor 1 (CRHR1) antagonists. In vivo, the chronic application of a CRHR1 antagonist after TxT resulted in reversal of the observed histological, molecular, and behavioral alterations. The data suggest that neuropsychiatric syndromes (i.e., delirium) after peripheral trauma might be at least in part due to the activation of the hippocampal CRH/NF-κB/BDNF pathway, which results in a dramatic loss of synaptic contacts. The successful rescue by stress hormone receptor antagonists should encourage clinical trials focusing on trauma-induced delirium and/or other posttraumatic syndromes.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32051550</pmid><doi>10.1038/s41380-020-0659-y</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-1486-8535</orcidid><orcidid>https://orcid.org/0000-0001-9935-6899</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2021-08, Vol.26 (8), p.3778-3794 |
issn | 1359-4184 1476-5578 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8550963 |
source | MEDLINE; Alma/SFX Local Collection |
subjects | 13/105 13/51 14/28 631/378 631/477 64/60 692/699/476/1414 82/79 Age Animals Antipsychotic drugs Autophagy Behavioral Sciences Biological Psychology Brain-derived neurotrophic factor Central nervous system Clinical trials Cognition Complications and side effects Corticotropin releasing hormone Delirium Development and progression Dosage and administration Drug therapy Health aspects Hippocampus Hippocampus (Brain) Hormone receptors Humans Lysosomes Medicine Medicine & Public Health Memory Memory Disorders - drug therapy Memory Disorders - etiology Memory, Disorders of Mice Motor activity Neurons Neurosciences NF-κB protein Phagocytosis Pharmacotherapy Physiological aspects Prevention Psychiatry Pyramidal cells Receptors, Corticotropin-Releasing Hormone Risk factors Synapses Syndrome Thorax Trauma Wounds and injuries |
title | A CRHR1 antagonist prevents synaptic loss and memory deficits in a trauma-induced delirium-like syndrome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A00%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20CRHR1%20antagonist%20prevents%20synaptic%20loss%20and%20memory%20deficits%20in%20a%20trauma-induced%20delirium-like%20syndrome&rft.jtitle=Molecular%20psychiatry&rft.au=Cursano,%20Silvia&rft.date=2021-08-01&rft.volume=26&rft.issue=8&rft.spage=3778&rft.epage=3794&rft.pages=3778-3794&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/s41380-020-0659-y&rft_dat=%3Cgale_pubme%3EA680437182%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2586676504&rft_id=info:pmid/32051550&rft_galeid=A680437182&rfr_iscdi=true |